{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:02:23Z","timestamp":1784804543519,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,23]]},"DOI":"10.7759\/cureus.113210","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:14:03Z","timestamp":1784801643000},"source":"Crossref","is-referenced-by-count":0,"title":["Glucocorticoid-Sparing Effect of Biologic Therapy in Rheumatoid Arthritis: A Single-Center Longitudinal Observational Study Comparing Rituximab With Tumor Necrosis Factor Inhibitors"],"prefix":"10.7759","author":[{"given":"Ilham","family":"Ben Marzouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"El Binoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Rostom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikram","family":"EL Moubarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Zemrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouchra","family":"AMINE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoutar","family":"Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Bahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen JS","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RB, Bergstra SA, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023, 82:3-18. 10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0889-8529(02)00064-6","article-title":"Glucocorticoid-induced osteoporosis","volume":"32","author":"Saag KG","year":"2003","unstructured":"Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am. 2003, 32:135-57. 10.1016\/s0889-8529(02)00064-6","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl C","year":"2016","unstructured":"Strehl C, Bijlsma JW, de Wit M, et al.. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016, 75:952-7. 10.1136\/annrheumdis-2015-208916","journal-title":"Ann Rheum Dis"},{"key":"ref4","article-title":"Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes","volume":"34","author":"Caplan L","year":"2007","unstructured":"Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol. 2007, 34:696-705.","journal-title":"J Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker017","article-title":"Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years","volume":"50","author":"Fardet L","year":"2011","unstructured":"Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford). 2011, 50:1982-90. 10.1093\/rheumatology\/ker017","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01744","article-title":"Glucocorticoids-all-rounders tackling the versatile players of the immune system","volume":"10","author":"Strehl C","year":"2019","unstructured":"Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids-all-rounders tackling the versatile players of the immune system. Front Immunol. 2019, 10:1744. 10.3389\/fimmu.2019.01744","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223986","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra SA","year":"2023","unstructured":"Bergstra SA, Sepriano A, Kerschbaumer A, et al.. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023, 82:81-94. 10.1136\/ard-2022-223986","journal-title":"Ann Rheum Dis"},{"key":"ref8","article-title":"Glucocorticoid tapering and discontinuation in rheumatoid arthritis: a review of the literature","volume":"5","author":"Wallace BI","year":"2023","unstructured":"Wallace BI, Waljee AK, Katz PP, et al.. Glucocorticoid tapering and discontinuation in rheumatoid arthritis: a review of the literature. ACR Open Rheumatol. 2023, 5:23-30.","journal-title":"ACR Open Rheumatol"},{"key":"ref9","article-title":"Glucocorticoids in the treatment of rheumatoid arthritis","volume":"33","author":"Bijlsma JW","year":"2015","unstructured":"Bijlsma JW, Jacobs JW, Buttgereit F. Glucocorticoids in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2015, 33:34-6.","journal-title":"Clin Exp Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.076299","article-title":"Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis","volume":"67","author":"Choy EH","year":"2008","unstructured":"Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, Scott DL. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis. 2008, 67:656-63. 10.1136\/ard.2007.076299","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30636-X","article-title":"Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial","volume":"396","author":"Burmester GR","year":"2020","unstructured":"Burmester GR, Buttgereit F, Bernasconi C, et al.. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet.  2020, 396:267-76. 10.1016\/S0140-6736(20)30636-X","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221957","article-title":"Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial","volume":"81","author":"Boers M","year":"2022","unstructured":"Boers M, Hartman L, Opris-Belinski D, et al.. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis. 2022, 81:925-36. 10.1136\/annrheumdis-2021-221957","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105671","article-title":"Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: results from the international TOCERRA and PANABA observational collaborative studies","volume":"91","author":"Lauper K","year":"2024","unstructured":"Lauper K, Mongin D, Bergstra SA, et al.. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: results from the international TOCERRA and PANABA observational collaborative studies. Joint Bone Spine. 2024, 91:105671. 10.1016\/j.jbspin.2023.105671","journal-title":"Joint Bone Spine"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226620","article-title":"Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial","volume":"84","author":"Ruyssen-Witrand A","year":"2025","unstructured":"Ruyssen-Witrand A, Brusq C, Masson M, et al.. Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial. Ann Rheum Dis. 2025, 84:49-59. 10.1136\/ard-2024-226620","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11584","article-title":"Lowering expectations: glucocorticoid tapering among veterans with rheumatoid arthritis achieving low disease activity on stable biologic therapy","volume":"5","author":"Wallace BI","year":"2023","unstructured":"Wallace BI, England BR, Baker JF, et al.. Lowering expectations: glucocorticoid tapering among veterans with rheumatoid arthritis achieving low disease activity on stable biologic therapy. ACR Open Rheumatol. 2023, 5:437-42. 10.1002\/acr2.11584","journal-title":"ACR Open Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002792","article-title":"Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)","volume":"9","author":"Adami G","year":"2023","unstructured":"Adami G, Fassio A, Rossini M, et al.. Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs). RMD Open. 2023, 9:002792. 10.1136\/rmdopen-2022-002792","journal-title":"RMD Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42371-z","article-title":"Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib","volume":"13","author":"Spinelli FR","year":"2023","unstructured":"Spinelli FR, Garufi C, Mancuso S, Ceccarelli F, Truglia S, Conti F. Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib. Sci Rep. 2023, 13:15537. 10.1038\/s41598-023-42371-z","journal-title":"Sci Rep"},{"key":"ref18","article-title":"Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study","volume":"34","author":"Saraux A","year":"2016","unstructured":"Saraux A, Rouanet S, Flipo RM, et al.. Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study. Clin Exp Rheumatol. 2016, 34:303-10.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/513773-glucocorticoid-sparing-effect-of-biologic-therapy-in-rheumatoid-arthritis-a-single-center-longitudinal-observational-study-comparing-rituximab-with-tumor-necrosis-factor-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:14:04Z","timestamp":1784801644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/513773-glucocorticoid-sparing-effect-of-biologic-therapy-in-rheumatoid-arthritis-a-single-center-longitudinal-observational-study-comparing-rituximab-with-tumor-necrosis-factor-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.113210","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}